MC
ITCI

Miramar Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Miramar Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22,550
Closed -$1.22M – 92
2023
Q1 		$1.22M Buy
22,550
+555
+3% +$26.8K 0.31% 34
2022
Q4 		$1.16M Hold
21,995
– – 0.31% 37
2022
Q3 		$1.1M Sell
21,995
-6,800
-24% -$355K 0.3% 38
2022
Q2 		$1.64M Buy
28,795
+350
+1% +$19.8K 0.47% 33
2022
Q1 		$1.74M Buy
+28,445
New +$1.48M 0.48% 37

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Miramar Capital's ITCI Position: Q2 2023 in Review

Miramar Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 22,550 shares — an estimated $1.22M sold.

Miramar Capital first reported a position in ITCI in Q1 2022 and held it in 5 quarters. The position peaked at $1.74M in Q1 2022. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Miramar Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Miramar Capital sold 22,550 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $1.22M.
  • Miramar Capital first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 5 quarters.
  • Miramar Capital's Intra-Cellular Therapies Inc. position peaked at $1.74M in Q1 2022.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Miramar Capital's 13F filing for Q2 2023, filed 11 Aug 2023.